Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nyse Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI

Capitalization	63.66B 54.66B 51.12B 47.75B 88.11B 5,722B 95.87B 593B 231B 2,712B 239B 234B 9,954B	P/E ratio 2018	-8.76x	P/E ratio 2019	-11.9x
Enterprise value	80.96B 69.52B 65.01B 60.73B 112B 7,277B 122B 754B 294B 3,450B 304B 297B 12,660B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
19/10/24	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
27/08/24	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
27/06/24	Allergan Aesthetics Debuts Alle Payment Plans	CI
05/03/24	Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	CI
18/09/23	Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence	CI
30/08/23	Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic)	CI
15/05/23	Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM®	CI
18/01/23	Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Share Price

Equities

AGN

IE00BY9D5467

Pharmaceuticals

Valuation: Allergan plc

Latest news: Allergan plc

Press Releases: Allergan plc

News in other languages: Allergan plc

Managers and Directors: Allergan plc

Other Pharmaceuticals

Financials

Company Profile

20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
06/05/20	Trump franchit le Rubicon

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	55	30/11/2016
Robert Michael PSD	President	54	07/05/2020

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	54	07/05/2020
Scott Reents BRD	Director/Board Member	-	07/05/2020
Ryan Quigley BRD	Director/Board Member	-	07/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	+1.16%	-3.86%	+24.27%	+175.25%	890B
JOHNSON & JOHNSON	+3.29%	+0.59%	+38.40%	+17.53%	498B
ABBVIE INC.	+0.98%	-2.20%	+28.18%	+38.10%	398B
ROCHE HOLDING AG	+0.11%	+4.10%	+26.14%	+6.53%	343B
ASTRAZENECA PLC	+0.90%	+1.04%	+29.57%	+20.30%	279B
NOVARTIS AG	+0.25%	-0.95%	+20.38%	+24.64%	252B
MERCK & CO., INC.	+0.75%	-4.55%	-3.35%	-10.26%	242B
NOVO NORDISK A/S	+2.40%	+3.11%	-60.10%	-30.92%	214B
AMGEN INC.	+0.49%	-8.70%	+14.37%	+13.18%	170B
Average	+0.62%	-1.58%	+13.10%	+28.26%	334.94B
Weighted average by Cap.	+0.70%	-1.81%	+19.18%	+56.93%

	2018	2019
Net sales	15.79B 13.56B 12.68B 11.84B 21.85B 1,419B 23.78B 147B 57.28B 673B 59.24B 57.99B 2,469B	16.09B 13.81B 12.92B 12.07B 22.27B 1,446B 24.23B 150B 58.37B 685B 60.38B 59.1B 2,516B
Net income	-5.1B -4.38B -4.09B -3.82B -7.05B -458B -7.68B -47.45B -18.49B -217B -19.12B -18.72B -797B	-5.27B -4.53B -4.23B -3.95B -7.3B -474B -7.94B -49.08B -19.12B -225B -19.78B -19.36B -824B
Net Debt	21.89B 18.8B 17.58B 16.42B 30.3B 1,968B 32.97B 204B 79.42B 933B 82.15B 80.41B 3,423B	17.3B 14.86B 13.9B 12.98B 23.95B 1,555B 26.06B 161B 62.78B 737B 64.94B 63.56B 2,706B